Mckesson CORP DEF 14A proxy statements

McKesson Corporation's 2026 proxy statement outlines board leadership transitions, executive compensation structures, and strategic priorities focused on healthcare services and AI integration.

McKesson Corporation reported robust fiscal year 2025 financial results, including significant revenue and earnings growth, alongside strategic advancements in oncology and biopharma services and enhanced corporate governance practices.

McKesson Corporation has filed its definitive proxy statement (DEFA14A) with the U.S. Securities and Exchange Commission, as required by Section 14(a) of the Securities Exchange Act of 1934.

McKesson Corporation's recent DEF 14A filing highlights a 25% stock price increase in fiscal year 2025, driven by disciplined execution of strategic priorities, including portfolio modernization and enhanced oncology and biopharma services, alongside robust corporate governance and a focus on people and culture.

McKesson's proxy statement highlights key governance updates, executive compensation structures, and strategic priorities for the upcoming year, including shareholder engagement and board composition.

McKesson Corporation has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

McKesson's 2024 proxy statement outlines the company's strategic priorities, governance updates, and executive compensation details, emphasizing shareholder engagement and long-term value creation.